Cambrex Corp., a manufacturer of small molecules and generic APIs, has agreed to acquire PharmaCore Inc., a company specializing in developing, manufacturing and scaling up small molecule APIs for clinical projects, for approximately $25 million. PharmaCore occupies a 35,000 sq.-ft. GMP site in High Point, NC, and has more than 60 employees.   PharmaCore develops and produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100 kg to sup...